Emerging strategies for EphA2 receptor targeting for cancer therapeutics.

ABSTRACT:

Importance of the field

High mortality rates with cancers warrant further development of earlier diagnostics and better treatment strategies. Membrane-bound erythropoietin-producing hepatocellular receptor tyrosine kinase class A2 (EphA2) is overexpressed in breast, prostate, urinary bladder, skin, lung, ovary and brain cancers.

Areas covered in this review

EphA2 overexpression in cancers, its signaling mechanisms and strategies to target its deregulation.

What the reader will gain

High EphA2 expression in cancer cells is correlated with a poor prognosis associated with recurrence due to enhanced metastasis. Interaction of the EphA2 receptor with its ligand (e.g., ephrinA1) triggers events that are deregulated and implicated in carcinogenesis. EphrinA1-independent onc

SUBMITTER: Tandon M 

PROVIDER: S-EPMC3016619 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature